Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Shares Outstanding (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Shares Outstanding for 16 consecutive years, with $44.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 2.21% to $44.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $44.6 million, a 2.21% increase, with the full-year FY2024 number at $44.1 million, up 1.56% from a year prior.
  • Shares Outstanding was $44.6 million for Q3 2025 at Harvard Bioscience, roughly flat from $44.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $47.7 million in Q1 2021 to a low of $40.5 million in Q2 2021.
  • A 5-year average of $42.9 million and a median of $42.7 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 3.41% in 2021, then dropped 13.53% in 2022.
  • Harvard Bioscience's Shares Outstanding stood at $41.1 million in 2021, then rose by 2.28% to $42.1 million in 2022, then grew by 3.12% to $43.4 million in 2023, then rose by 1.56% to $44.1 million in 2024, then increased by 1.15% to $44.6 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Shares Outstanding are $44.6 million (Q3 2025), $44.5 million (Q2 2025), and $44.2 million (Q1 2025).